We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Molecular Testing Useful for Genetic Retinal Diseases

By HospiMedica staff writers
Posted on 20 Feb 2007
Among patients with retinal disease, molecular testing can confirm a clinical diagnosis of hereditary disorders, identify carrier status, and confirm or rule out the presence of a familial mutation in those without symptoms.

The signs and symptoms of diseases of the retina, the light-sensitive membrane at the back of the eye that transmits images to the brain's optic nerve, overlap frequently, according to background information in an article in the February 2007 issue of Archives of Ophthalmology. More...
This can make a precise diagnosis difficult. Molecular testing, which screens for specific genetic mutations, is available for more than 950 genetic diseases, including many involving the eye.

Katy Downs, M.S., from the University of Michigan Kellogg Eye Center (Ann Arbor, MI, USA) and colleagues assessed the utility, scope, and limitations of molecular testing in 350 tests performed at one laboratory: 266 diagnostic, nine predictive and 75 for carrier status. Blood samples were submitted with a genetic test request form that included patient name, date of birth, sex, ethnic background, test(s) needed, indication for referral, family history depicted in pedigree format, and the DNA testing consent form signed by the patient or the parent or guardian of a pediatric patient, the authors wrote. DNA was isolated from the blood samples and eight genes with mutations known to be involved with the retina were analyzed.

The molecular basis of the disease was determined in 133 of 266 diagnostic tests; the disease-causing mutations were not identified in the remaining 133 diagnostic tests, the authors wrote. Of the nine predictive tests performed, five determined that the non-symptomatic individual did carry the same gene mutation as his or her affected relative, while four did not. Of the 75 females who underwent testing to confirm their carrier status, 47 were carriers of a mutation linked to retinal disease.

The most common use of molecular diagnostic information of patients with retinal disease is to confirm a clinical diagnosis. The clinical presentation often was not straightforward, and the differential diagnosis could include several diseases. Molecular diagnostics does not replace the necessary expertise of the ophthalmologist; rather, it adds a new tool to the ophthalmologist's diagnostic arsenal.

The authors concluded, Molecular testing will likely become a standard of practice for the ophthalmologist. Because ocular molecular testing is still in its infancy, the ophthalmologist may encounter direct patient requests for testing and will need to determine when to order tests. Clinical molecular diagnostic laboratory personnel, including the laboratory director, the genetic counselor, and the clinical ophthalmic genetic specialist, can be of great value to the ophthalmologist by providing consultation before and after molecular genetic testing.





Related Links:
University of Michigan Kellogg Eye Center

New
Gold Member
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Rapid Sepsis Test
SeptiCyte RAPID
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.